Full Text:
<6>
CLC number:
On-line Access: 2025-03-22
Received: 2024-08-23
Revision Accepted: 2025-01-01
Crosschecked: 0000-00-00
Cited: 0
Clicked: 8
|
A redox-responsive nanovaccine for cytosolic delivery of antigen and adjuvant to enhance cancer immunotherapy
| |||||||||||||
Taisheng Liu,Bingkai He,Jiaqing Tao,Shaoying He,Nanlin Fu,Kewei Wang,Hui Fan. A redox-responsive nanovaccine for cytosolic delivery of antigen and adjuvant to enhance cancer immunotherapy[J]. Journal of Zhejiang University Science D, 2025, 8(4): 625638.
@article{title="A redox-responsive nanovaccine for cytosolic delivery of antigen and
adjuvant to enhance cancer immunotherapy",
author="Taisheng Liu,Bingkai He,Jiaqing Tao,Shaoying He,Nanlin Fu,Kewei Wang,Hui Fan",
journal="Journal of Zhejiang University Science D",
volume="8",
number="4",
pages="625638",
year="2025",
publisher="Zhejiang University Press & Springer",
doi="10.1631/bdm.2400339"
}
%0 Journal Article
%T A redox-responsive nanovaccine for cytosolic delivery of antigen and
adjuvant to enhance cancer immunotherapy
%A Taisheng Liu
%A Bingkai He
%A Jiaqing Tao
%A Shaoying He
%A Nanlin Fu
%A Kewei Wang
%A Hui Fan
%J Journal of Zhejiang University SCIENCE D
%V 8
%N 4
%P 625638
%@ 1869-1951
%D 2025
%I Zhejiang University Press & Springer
%DOI 10.1631/bdm.2400339
TY - JOUR
T1 - A redox-responsive nanovaccine for cytosolic delivery of antigen and
adjuvant to enhance cancer immunotherapy
A1 - Taisheng Liu
A1 - Bingkai He
A1 - Jiaqing Tao
A1 - Shaoying He
A1 - Nanlin Fu
A1 - Kewei Wang
A1 - Hui Fan
J0 - Journal of Zhejiang University Science D
VL - 8
IS - 4
SP - 625638
EP -
%@ 1869-1951
Y1 - 2025
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/bdm.2400339
Abstract: Cancer vaccines have garnered significant attention in cancer immunotherapy because they trigger tumor-specific immune
responses. However, their effectiveness is hindered by inefficient antigen and adjuvant delivery at the subcellular level,
which is essential to stimulate a robust CD8+ T cell response. This study presents PAR/OVA, a cancer nanovaccine devel?
oped by combining imiquimod (R837)-modified polyamidoamine dendrimers with the model protein antigen ovalbumin
(OVA). Within the nanovaccine, R837 is an adjuvant for the Toll-like receptor 7 (TLR7) pathway and a structural compo?
nent that facilitates OVA loading. In dendritic cells (DCs), the high cytoplasmic glutathione levels triggered the breakdown
of PAR/OVA, releasing OVA and R837, which induced DC activation and antigen cross-presentation. Furthermore, PAR/
OVA vaccination showed a protective effect and effectively inhibited B16-OVA tumor progression, indicating its potential
in cancer immunotherapy. Combining this vaccine with an immune checkpoint blockade enhanced antitumor efficacy by
improving the ability of cytotoxic T lymphocytes to target cancer cells within the tumor microenvironment. These findings
underscore the potential of this adjuvant/antigen-delivering nanovaccine in cancer immunotherapy.
Open peer comments: Debate/Discuss/Question/Opinion
<1>